Investing.comCodex · 实盘不做把握 8/10
北京时间·🕒 发布 04:04:40时区推断·⟳ 抓取 04:06:12·⚡ 决策 07-28 04:06:47 +35s·92.0 天前
Kymera Therapeutics 任命 Terence Rooney 为首席医疗官
本次只是临床期生物医药公司常规高管任命，未披露临床数据、监管进展、融资、合作或商业化金额。
📄 原文Investing.com↗ 原文
Kymera Therapeutics names Terence Rooney as chief medical officer
Oil prices tumble after U.S. and Iran pause fighting, Brent falls below $90 WATERTOWN, Mass. - Kymera Therapeutics, Inc…
不做 Kymera Therapeutics（KYMR.US）
普通 CMO 任命不改变短期收入、现金流、临床成功概率或监管路径，无法形成正期望交易，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-27 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次只是临床期生物医药公司常规高管任命，未披露临床数据、监管进展、融资、合作或商业化金额。
主要风险
- 若后续伴随管线战略调整、关键临床读出或合作交易披露，需要按新事件重新研判。
原文全文
展开原文 · 1,985 字
Oil prices tumble after U.S. and Iran pause fighting, Brent falls below $90
WATERTOWN, Mass. - Kymera Therapeutics, Inc. (NASDAQ:KYMR) announced Monday the appointment of Terence Rooney, MD, as Chief Medical Officer, according to a press release statement.
Dr. Rooney will lead the company’s global clinical development strategy and oversee the advancement of its oral immunology portfolio across multiple immuno-inflammatory diseases. He succeeds Jared Gollob, MD, who will retire after eight years with the company and remain as an advisor through the end of the year.
Prior to joining Kymera, Dr. Rooney served as Senior Vice President, Portfolio and Asset Management Leader, Immunology, at Johnson & Johnson, where he led global compound development teams and portfolio strategy and operations. He previously held senior leadership roles across immunology research and development at Eli Lilly and Roche.
Dr. Rooney has contributed to marketing applications for medicines including ICOTYDE®, IMAAVY®, OLUMIANT®, STELARA®, and TREMFYA®. His career has spanned work with small molecules, peptides, biologics and cell therapies across therapeutic areas including dermatology, respiratory, rheumatology, gastroenterology and rare diseases.
Dr. Rooney received his medical degrees from the Royal College of Surgeons in Ireland and completed training in internal medicine at the Dublin Academic Teaching Hospitals. He completed rheumatology fellowships in Ireland and at the University of California, San Francisco, and received a doctorate from the National University of Ireland. He has authored approximately 50 peer-reviewed scientific publications.
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule degrader medicines for immunological diseases. The company was founded in 2016 and is based in Watertown, Massachusetts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
WATERTOWN, Mass. - Kymera Therapeutics, Inc. (NASDAQ:KYMR) announced Monday the appointment of Terence Rooney, MD, as Chief Medical Officer, according to a press release statement.
Dr. Rooney will lead the company’s global clinical development strategy and oversee the advancement of its oral immunology portfolio across multiple immuno-inflammatory diseases. He succeeds Jared Gollob, MD, who will retire after eight years with the company and remain as an advisor through the end of the year.
Prior to joining Kymera, Dr. Rooney served as Senior Vice President, Portfolio and Asset Management Leader, Immunology, at Johnson & Johnson, where he led global compound development teams and portfolio strategy and operations. He previously held senior leadership roles across immunology research and development at Eli Lilly and Roche.
Dr. Rooney has contributed to marketing applications for medicines including ICOTYDE®, IMAAVY®, OLUMIANT®, STELARA®, and TREMFYA®. His career has spanned work with small molecules, peptides, biologics and cell therapies across therapeutic areas including dermatology, respiratory, rheumatology, gastroenterology and rare diseases.
Dr. Rooney received his medical degrees from the Royal College of Surgeons in Ireland and completed training in internal medicine at the Dublin Academic Teaching Hospitals. He completed rheumatology fellowships in Ireland and at the University of California, San Francisco, and received a doctorate from the National University of Ireland. He has authored approximately 50 peer-reviewed scientific publications.
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule degrader medicines for immunological diseases. The company was founded in 2016 and is based in Watertown, Massachusetts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。